Summary
[More than 20 listed pharmaceutical companies disclosed the status of drug shortlistings. Innovative drugs have accelerated their advancement in medical insurance. Approved varieties have been included in multiple years.]The National Medical Insurance Administration recently announced the 2021 National Medical Insurance Drug List, and 74 new drugs have been added to the list. Among them, 7 kinds of non-exclusive drugs were directly transferred into the catalog, and 67 kinds of drugs were included through negotiation. The new version of the medical insurance catalogue will be formally implemented from January 1 next year. At present, the pace of innovative drugs entering the medical insurance catalog is accelerating. The reporter combed through the announcements of listed companies and found that as of press time, more than 20 listed pharmaceutical companies have disclosed the shortlisted status of drugs, including a batch of Class 1 new drugs from Hengrui Pharmaceuticals, BeiGene, Betta Pharmaceuticals, Zejing Pharmaceuticals, Iris and other companies Entered for the first time, many of which were approved for marketing within the year. (Economic Information Daily)
The National Medical Insurance Administration recently announced the 2021 National Medical Insurance Drug List, and 74 new drugs have been added to the list. Among them, 7 kinds of non-exclusive drugs were directly transferred into the catalog, and 67 kinds of drugs were included through negotiation. The new version of the medical insurance catalogue will be formally implemented from January 1 next year. At present, the pace of innovative drugs entering the medical insurance catalog is accelerating.Reporter based on the listingCompany AnnouncementAccording to a review, as of press time, more than 20 listed pharmaceutical companies have disclosed the status of drug finalists.Hengrui Medicine、BeiGene、Betta PharmaceuticalsFor the first time, a batch of Class 1 new drugs from companies such as Zejing Pharmaceuticals and Iris entered into the market for the first time, and many of them were approved for listing during the year.
(Source: Economic Information Daily)
.